Ascendis Pharma A/S (NASDAQ:ASND) Downgraded by StockNews.com to “Sell”

StockNews.com cut shares of Ascendis Pharma A/S (NASDAQ:ASNDFree Report) from a hold rating to a sell rating in a research note published on Wednesday morning.

Several other equities analysts have also recently weighed in on the stock. Morgan Stanley reaffirmed an equal weight rating and set a $116.00 target price on shares of Ascendis Pharma A/S in a research note on Monday, April 22nd. JPMorgan Chase & Co. raised their price objective on Ascendis Pharma A/S from $167.00 to $170.00 and gave the company an overweight rating in a research report on Friday, May 3rd. Citigroup boosted their target price on Ascendis Pharma A/S from $146.00 to $182.00 and gave the stock a buy rating in a research report on Thursday, February 8th. Cantor Fitzgerald reissued an overweight rating and set a $173.00 price target on shares of Ascendis Pharma A/S in a research note on Wednesday. Finally, Wells Fargo & Company lifted their price objective on Ascendis Pharma A/S from $260.00 to $262.00 and gave the stock an overweight rating in a research note on Friday, May 3rd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Ascendis Pharma A/S presently has an average rating of Moderate Buy and an average price target of $173.88.

Check Out Our Latest Analysis on Ascendis Pharma A/S

Ascendis Pharma A/S Trading Down 0.6 %

Shares of NASDAQ:ASND opened at $124.04 on Wednesday. Ascendis Pharma A/S has a 12-month low of $83.75 and a 12-month high of $161.00. The company has a market cap of $7.22 billion, a PE ratio of -12.91 and a beta of 0.54. The stock has a 50 day moving average of $143.60 and a 200 day moving average of $130.20.

Institutional Trading of Ascendis Pharma A/S

Several institutional investors have recently made changes to their positions in the stock. Certuity LLC acquired a new stake in shares of Ascendis Pharma A/S during the fourth quarter worth $270,000. Invesco Ltd. grew its position in Ascendis Pharma A/S by 9.3% during the 3rd quarter. Invesco Ltd. now owns 672,126 shares of the biotechnology company’s stock worth $62,938,000 after purchasing an additional 57,413 shares in the last quarter. J.P. Morgan Private Wealth Advisors LLC purchased a new stake in shares of Ascendis Pharma A/S in the third quarter worth approximately $1,810,000. Schonfeld Strategic Advisors LLC boosted its position in Ascendis Pharma A/S by 24.7% during the third quarter. Schonfeld Strategic Advisors LLC now owns 38,900 shares of the biotechnology company’s stock valued at $3,643,000 after purchasing an additional 7,700 shares during the last quarter. Finally, Sequoia Financial Advisors LLC acquired a new position in Ascendis Pharma A/S during the fourth quarter worth $732,000.

About Ascendis Pharma A/S

(Get Free Report)

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.

Further Reading

Analyst Recommendations for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.